Buy, Sell or Hold MRK Stock: Key Factors to Watch Before Q4 Earnings

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

• In the last reported quarter, the company delivered an earnings surprise of 9.32%

  80% confidence

• Keytruda will lose patent exclusivity in 2028

  80% confidence

• The Zacks Consensus Estimate for Bridion is $457.0 million

  80% confidence

• Merck shares currently trade at 15.62 forward earnings, significantly lower than 18.18 for the industry

  80% confidence

• Merck's phase III pipeline has almost tripled since 2021, supported by in-house pipeline progress and M&A deals

  80% confidence

• Dual PD-1/VEGF inhibitors like Summit Therapeutics' ivonescimab are designed to overcome the limitations of single-target therapies like Keytruda

  80% confidence

• The Zacks Consensus Estimate for the Animal Health unit is $1.48 billion

  80% confidence

• The stock is trading above its five-year mean of 12.48

  80% confidence

• Merck delivered a four-quarter earnings surprise of 5.08%, on average

  80% confidence

• The Zacks Consensus Estimate for Gardasil is $1.04 billion

  80% confidence

• Earnings estimates for 2026 have declined from $8.50 to $6.54 per share over the past 30 days, probably due to costs related to Merck's various M&A deals

  80% confidence

• The Zacks Consensus Estimate for Merck's Pharmaceutical unit is $14.66 billion

  80% confidence

• The Zacks Consensus Estimate for fourth-quarter sales is $16.19 billion

  80% confidence

• The Zacks Consensus Estimate for Keytruda's sales is $8.31 billion

  80% confidence

• Short-term investors may stay away from MRK stock for now as there seems to be limited upside from current levels

  80% confidence

• Ohtuvayre has multibillion-dollar commercial potential

  80% confidence

• Merck is positioned to launch around 20 new vaccines and drugs over the next few years, with many having blockbuster potential

  80% confidence

• The Zacks Consensus Estimate for fourth-quarter earnings is $2.04 per share

  80% confidence

• Capvaxive and Winrevair have the potential to generate significant revenues over the long term

  80% confidence

• Merck has an Earnings ESP of +0.33% and a Zacks Rank #4 (Sell)

  80% confidence

Data points we hold from this source